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1. Introduction
Early diagnosis of tuberculosis and drug resistance improves survival and by identifying in‐
fectious cases promotes contact tracing, implementation of institutional cross-infection pro‐
cedures, and other public-health actions. There have been many advances in methodology
for tuberculosis diagnosis [1-3].
For every stages of diagnosis, there are new approaches. New tests are available by level of
laboratory and phase of application.
2. Microscoby
Microscopy has been a diagnostic tool for TB for over a century, and still currently the most
rapid diagnostic method. Standard light microscopy (LM) and fluorescent microscopy (FM)
are common methods. The recent development of light emitting diodes (LED), with the ap‐
propriate fluorescent light output for FM and low power consumption, has led to the devel‐
opment of simple, robust LED FM microscopes, requiring minimal mains or battery power
and no dark room requirement. The WHO has recommended rolling it out as an alternative
to LMs in resource-limited settings, based on studies that have shown comparable perform‐
ance of LM and standard FM systems [4,5].
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3. Culture and drug resistance testing
3.1. Phenotypic methods
Significant effort has been invested into further development of simple, alternative pheno‐
typic methods such as the nitrate reductase assay (NRA), thin-layer agar (TLA), colour test
(Color Test), the microscopic observation drug susceptibility assay (MODS), the colorimetric
redox indicator (CRI) method and phage-based assays, most of which can be set up directly
on specimens [6,7,8]. These methods can detect MTB and resistance to INH and RMP. While
MODS, NRA and CRI have been endorsed by the WHO, current evidence was considered to
be insufficient for recommending the use of TLA or phage-based assays [8].
MODS is an extensively validated method that has almost perfect agreement with conven‐
tional DST for INH, RMP and MDR-TB (100%, 97% and 99%). The results are available with‐
in a median of 7 days; the method is cheap, non-commercial and works well on all types of
primary specimens as well as on isolates. However, it requires relatively long, detailed staff
training. [6,7,9,10]
TLA recently demonstrated a good performance of the MDR-/XDR-TB colour test for the
identification of MTB complex and detection of resistance to INH, RMP and ciprofloxacin in
cultures [11].
3.2. Genotypic methods
Molecular techniques are aimed at the nucleic acid of the mycobacterium as the analyte. Ri‐
bosomal rRNA is useful genetic target for the identification of organisms, since it often con‐
tains spesific sequences and is present in the cells and media in high quantity due to the
growth of the mycobacteria. There are various applications of molecular tecniques for the
detection and identification of MTB.
PCR is the common format of nucleic acid amplification tests (NAAT); other methodologies
include ligase chain reaction, strain displacement amplification, loop-mediated isothermal
amplifi cation (LAMP) and transcription mediated amplification. More recently, real-time
(RT) PCR technologies based on fluorescent- probe detection or melting-curve analysis have
been developed [12-16].
These molecular techniques also aimed detecting resistance genes. Example includes; DNA
probe and DNA sequencing of MTB gene such as catalase (katG) or RNA polymerase
(rpoB). Mutations in these genes have been associated with resistance to isoniazid and ri‐
fampicin respectively. The using of molecular primers in real- time PCR reaction can differ‐
entiate between the presence of the wild- type sequence and mutated sequence associated
with drug resistance. Molecular tests are rapid (within few hours), highly sensitive and spe‐
cific, but expensive, requires expertise and may not differentiate active infection as DNA
from a dead organism during antibiotic treatment can be detected and amplified by PCR
[17]. Genotypic methods are not routinely used in the mycobacterium laboratory; they are
essentially for research purposes [18,19].
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Line-probe assays and XPERT MTB/RIF: Line probe assays (LPAs) are actual molecular
tests. Three main LPAs for the rapid diagnosis of TB and/or rapid detection of RMP resist‐
ance and MDR-/XDR-TB are currently available on the market: INNO-LiPA Rif. TB (Innoge‐
netics, Belgium), GenoType®MTBDR/MTBDRplus and Geno-Type® MTBDRsl (both Hain
Lifescience, Germany). These assays are based on the targeted amplification (PCR) of specif‐
ic fragments of the MTB genome, followed by hybridisation of PCR products to oligonucleo‐
tide probes immobilised on membranes. INNO-LiPA Rif TB detects only RMP resistance,
GenoType MTBDR/MTBDRplus detects both RMP and INH resistance, and GenoType
MTBDRsldetects resistance to flouroquinolons, injectable second-line drugs and ethambutol.
These tests are designed for detection the MTB isolates in respiratory specimens. Xpert®
MTB/RIF (Cepheid Inc, USA) is a fully automated RT-PCR based assay for the detection of
TB bacteria and resistance to RMP in direct clinical specimens [20].
4. Lysis-centrifugation blood culture system
The recovery of mycobacterium from peripheral blood and bone marrow samples may be
improved by lyses- centrifugation blood culture method. In this method, blood is put into a
tube containing an anticoagulant and an agent to effect rupture of both erythrocytes and
neutrophils. Following centrifugation of the tube, the sediment is inoculated into the appro‐
priate culture media. This method has increased both the yield and shortened the time of
recovery of mycobacteria from blood cultures [21].
5. Phage Amplification Technique (PAT)
This is a bacteriophage based test to detect MTB in sputum. Non-pathogenic mycobacteria
(sensor cells) were used for control bacteria in the test. The phage replicate, infect and lyses
the sensor cells leaving zones of clearing (holes) in the agar. The areas of clearing indicates
that the patient sputum contain viable MTB. It is fast with a turnaround time of 2 days. It is
cheap, requires few equipments, sensitive (detection as low as 100 tubercles per ml of spu‐
tum). It can be adapted for sensitivity testing. Limitations are applicability to sputum speci‐
men only and technically demanding [22].
6. Immunological methods
Immunodiagnostic tests can provide indirect evidence current or past infections of MTB. Ex‐
ception of tuberculin skin test, immunodiagnostic tests are of limited application due to
cross reactivity and poor sensitivity.
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6.1. Detection of antibodies
Although the detection of antibodies against MTB in the blood is a relatively simple and
costeffective method, recent meta-analyses and systematic reviews concluded that commer‐
cial serological tests provided inconsistent results [23,24]. As the overall test performance
and data quality of these assays were poor, the WHO currently recommends against their
use for the diagnosis of pulmonary and extrapulmonary TB.
Antibodies against lipoarabinomannans, A60, 38Kd and 16 Kd are mostly studied [25].
6.2. Detection of antigens
Lipoarabinomannan (LAM) was identified as a promising target for antigen detection for TB
diagnosis due to its temperature stability and could be detected in urine. LAM-based assays
are currently being developed by a number of commercial companies, and preliminary re‐
sults indicate their potential applicability in the rapid diagnosis of TB by detecting LAM in a
variety of body fluids, including urine [26]. LAM-based assays are included in the WHO TB
diagnosis re-tooling programme [27] and forma part of a Foundation for Innovative New
Diagnostics (FIND) funded TB Project [19,28].
MTB antigen detection provides direct evidence of TB. Such as LAM, 65Kd, 14 Kd antigens
were widely used. It is very quick and easy to perform. Main limitation is low sensitivity
(detect high levels of antibody). It does not rule out TB in patients with poor antibody re‐
sponse as in HIV and malnutrition and not specific due to cross reactivity with other species
of mycobacteria in the environment [26].
7. Interferon-Gamma Release Assays (IGRA)
Because  of  the  difficulties  with  the  tuberculin  test  interpretation,  the  interferon-gamma
assay test was developed. Two available formats of the interferon-gamma release assays
are; the Quantiferon-TB Gold and T Spot-TB test. The IGRA assay is based on the ability
of the MTB antigens, which includes the Early Secretory Antigen Target 6 (ESAT-6) and
Culture  Filtrate  Protein 10 (CFP-10)  to  stimulate  host  production of  interferon –gamma.
These antigens are not present in NTM or in BCG vaccine, so, these tests can distinguish
latent TB infection from BCG immunization and NTM infections. Requiring a single visit
to  draw  a  blood  sample  and  result  available  within  24  hours  are  main  advantages.  It
does not boost immune response measured by subsequent tests which can happen with
tuberculin skin test.  It  does not  cause to readers bias  as  in tuberculin skin test  and not
affected by prior BCG vaccination.  Blood must be processed within 12 hours while leu‐
kocytes are still viable. There are limited data for sensitivity of IGRAs in children young‐
er 17 years of age and immunocompromised patients e.g. HIV/AIDS, diabetics, treatment
with immunosuppressive drugs [29].
Tuberculosis - Current Issues in Diagnosis and Management146
8. The future of TB diagnostics
The rapid technological evolution in the laboratory diagnosis of TB, especially in the ap‐
plication  of  molecular  biology  h  as  diminished the  time  required  for  identification  and
susceptibility  testing.  Continuous effort  endeavor for  increasing reproducibility,  improv‐
ment of performance and cost containment. WHO founded an organisation (FIND-Foun‐
dation for Innovative New Diagnostics) for researching fast, relible and inexpensive tests
as given Table 1 [28].
Concept phase Feasibility
phase
Devolapment
phase
Evaluation
phase
Demonstration
phase
Implementation
phase
Reference
laboratory level
- - - - - Liquid culture &
DST
Rapid speciation
Line probe assay
(1st line drugs)
Disrtict/peripheral
level
- Rapid
colorimetric
DST
- Line probe
assay /2nd line
drugs)
LAMP TB LED florecence
microscopy
Xpert MTB/RIF
Community level LFI sensitivity
increase
Antibody
detection
Antigen
detection
Beta lactamase
detection
- - -
LFI sensitivity increase: Alternative quantitative fluorescence (LFI) sensitivity increase
Table 1. WHO projects for TB diagnostic tests. LAMP TB: Loop mediated isothermal amplification (LAMP) for TB
9. Assays being developed/evaluated
Another new approach to diagnosis of TB is biosensing technologies. Variety of portable,
rapid, and sensitive biosensors with immediate “on-the-spot” interpretation have been de‐
veloped for MTB detection based on different biological elements recognition systems and
basic signal transducer principles. Combination of nanotechnology and biosensing technolo‐
gy has very promising.
Transrenal DNA detection provides a challenging new target for molecular TB diagnosis.
No commercial assays are currently available, largely due to the difficulties in the develop‐
ment of TB detection/read-out assays.
Combined high-resolution melting (HRM) curve analysis using a closed-tube RT-PCR is po‐
tentially an ideal screening method with a positive predictive value (PPV) of 100% and neg‐
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ative predictive value (NPV) of at least 99.9%, for screening large specimen numbers in any
TB laboratory.
New amplification methodologies and refinements of ‘molecular beacon’ approaches, such
as linear-after-the exponential PCR, offer future improvements, particularly in drug resist‐
ance analysis [30-32].
MTB urease is a bacterial virulence factor. Isotopcally labelled urea as substrate, Urea tracer
has detected in exaled breath using portable infrared spectrofotometer. Signal correleted
with bacterial load. [33]
A biophotonic detection platform has been developed that utilizes reporter enzyme fluores‐
cence to detect β-lactamase produced by MTB. This innovative new technology is now being
adapted for point of care (POC) use [28]
10. Conclusions and further work
This is an exciting time for new TB diagnostics. This is in part a reflection of the funding and
application of good science, a clear understanding of unmet needs, a commercial sector that
is considering new approaches to a global market, and the complexity of and limited prog‐
ress in new drug and vaccine development, which has encouraged more academic and in‐
dustrial partners to participate in diagnostic development.
Overall, the technology for the diagnosis of TB and RMP resistance in pulmonary specimens
is well advanced, with high specificity and increasingly high sensitivity. Rapid, high-specif‐
icity molecular assays for TB identification and drug resistance cannot replace the standard
diagnostic methods, such as microbiology, clinical and radiological assessments, and con‐
ventional DST for active TB in pulmonary (particularly sputum smear-negative) and extra-
pulmonary TB specimens. Implementation of all of these tools in routine laboratory practice
requires the implementation of appropriate quality assurance systems.
The performance of molecular tools of extra-pulmonary specimens varies and should be
considered separately for each specifi c specimen type. Evidence for the use of these assays
to identify TB and detect drug resistance in TB-HIV co-infected individuals is limited. There
is a need for designed studies among children, including HIV-positive children. There also
remains a need to increase the sensitivity of TB detection among all patients, but especially
among immunocompromised patients and children [20].
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